Kerendia is a medication that has been approved by the FDA for the treatment of chronic kidney disease in adults with type 2 diabetes. This drug is a combination of two active ingredients, finerenone and empagliflozin, which work together to help improve kidney function and reduce the risk of cardiovascular events in patients with this condition.

Finerenone is a mineralocorticoid receptor antagonist that helps to block the effects of hormones that can contribute to kidney damage and cardiovascular complications. Empagliflozin, on the other hand, is a sodium-glucose co-transporter 2 (SGLT2) inhibitor that helps to reduce the amount of glucose reabsorbed by the kidneys, leading to improved glycemic control and reduced strain on the kidneys.

Patients who are prescribed Kerendia should take it as directed by their healthcare provider, typically once daily with or without food. It is important to follow the dosing instructions carefully and not to exceed the recommended dose.

As with any medication, Kerendia may cause side effects in some patients. Common side effects may include dizziness, dehydration, and changes in kidney function. It is important to report any side effects to your healthcare provider promptly.

Overall, Kerendia is a valuable treatment option for patients with chronic kidney disease and type 2 diabetes. It has been shown to be effective in improving kidney function and reducing the risk of cardiovascular events in this patient population. If you have been diagnosed with chronic kidney disease and type 2 diabetes, talk to your healthcare provider to see if Kerendia may be a suitable treatment option for you.